Capricor Therapeutics, Inc.
CAPR · NASDAQ
Company research
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to advancing transformative cell and exosome-based therapeutics for rare diseases with significant unmet medical needs. The company's lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy currently in Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD), a rare and fatal muscle-degenerating disease. In addition to its cell therapy program, Capricor is leveraging its proprietary StealthX™ exosome platform to engineer next-generation therapeutics and vaccines capable of delivering nucleic acids, proteins, and small-molecule therapeutics across a broad range of diseases. Led by CEO Linda Marbán, Ph.D., since 2010, the company maintains academic partnerships with leading research institutions including Johns Hopkins University and Cedars-Sinai Medical Center to support its translational drug development approach.
Research reports
Analysis frames CAPR as deeply undervalued versus their fair value estimate, with strong forecast earnings growth and substantial upside to consensus analyst price targets, while flagging negligible current revenue and recent shareholder dilution as key risks.
JaguarAnalytics · March 12, 2026CAPR — Capricor Therapeutics, Inc. (Hidden Angle)The CAPR section highlights newly disclosed DVA Eat‑10‑Bites data showing 83% slowing of functional swallowing decline versus placebo and strong physician enthusiasm, combined with an August 22, 2026 PDUFA date for deramiocel, arguing that the Street has not yet repriced the increased approval probability and near‑term upside despite remaining regulatory and execution risks.
Analystock.ai · November 24, 2025Capricor Therapeutics, Inc. (CAPR) Investment Case ReportThis investment case report lays out a structured thesis around deramiocel/Daramycin and Capricor’s exosome platform, noting imminent HOPE‑3 Phase 3 results, a strong safety profile, very large modeled revenue growth and a cash runway into 2026, but also emphasizing sizable current losses, high valuation multiples, dependence on external funding, and material regulatory and competitive risks.